| Authors: |
Kirkwood JM; UPMC Hillman Cancer Center, Pittsburgh, PA, USA. kirkwoodjm@upmc.edu., Del Vecchio M; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Weber J; NYU Langone Medical Center, New York, NY, USA., Hoeller C; Medizinische Universität Wien, Vienna, Austria., Grob JJ; Hôpital de la Timone, Marseille, France., Mohr P; Elbe Klinikum Buxtehude, Buxtehude, Germany., Loquai C; University Medical Center Mainz, Mainz, Germany., Dutriaux C; Hôpital Saint André, Bordeaux, France., Chiarion-Sileni V; Istituto Oncologico Veneto, IOV-IRCCS, Padova, Italy., Mackiewicz J; Institute of Oncology, Poznan University of Medical Sciences, Poznan, Poland., Rutkowski P; Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Arenberger P; Charles University Third Faculty of Medicine and University Hospital Královské Vinohrady, Prague, Czech Republic., Quereux G; Nantes University Hospital, Nantes, France., Meniawy TM; University of Western Australia and Sir Charles Gairdner Hospital, Perth, WA, Australia., Ascierto PA; Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy., Menzies AM; Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia., Durani P; Bristol Myers Squibb, Princeton, NJ, USA., Lobo M; Bristol Myers Squibb, Princeton, NJ, USA., Campigotto F; Bristol Myers Squibb, Princeton, NJ, USA., Gastman B; Cleveland Clinic, Cleveland, OH, USA., Long GV; Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia. |
